A

Aurisco Pharmaceutical Co Ltd
SSE:605116

Watchlist Manager
Aurisco Pharmaceutical Co Ltd
SSE:605116
Watchlist
Price: 21.12 CNY -4.91% Market Closed
Market Cap: 8.5B CNY
Have any thoughts about
Aurisco Pharmaceutical Co Ltd?
Write Note
Aurisco Pharmaceutical Co Ltd
/
Balance Sheet
/
Cash

Aurisco Pharmaceutical Co Ltd
Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Aurisco Pharmaceutical Co Ltd
Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash CAGR 3Y CAGR 5Y CAGR 10Y
A
Aurisco Pharmaceutical Co Ltd
SSE:605116
Cash
¥534m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash
¥22.4B
CAGR 3-Years
74%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash
¥8.8B
CAGR 3-Years
59%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash
¥22.3B
CAGR 3-Years
16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash
¥14.1B
CAGR 3-Years
2%
CAGR 5-Years
N/A
CAGR 10-Years
160%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash
¥391.7m
CAGR 3-Years
1 693%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Aurisco Pharmaceutical Co Ltd
Glance View

Market Cap
8.6B CNY
Industry
Pharmaceuticals

Aurisco Pharmaceutical Co., Ltd. engages in the development and production of pharmaceutical chemicals. The company is headquartered in Taizhou, Zhejiang and currently employs 1,207 full-time employees. The company went IPO on 2020-09-21. The firm's main products are respiratory, cardiovascular, anti-infective and nervous system drugs, including flumethasone, fluticasone propionate, eplerenone, tenofovir, pregabalin and other APIs and intermediates. The firm distributes its products in domestic market and to overseas markets.

Intrinsic Value
34.48 CNY
Undervaluation 39%
Intrinsic Value
Price
A
What is Intrinsic Value?

See Also

What is Aurisco Pharmaceutical Co Ltd's Cash?
Cash
534m CNY

Based on the financial report for Dec 31, 2023, Aurisco Pharmaceutical Co Ltd's Cash amounts to 534m CNY.

What is Aurisco Pharmaceutical Co Ltd's Cash growth rate?
Cash CAGR 1Y
57%

Over the last year, the Cash growth was 57%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 201,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.